Risk – Page 2 – Talk Bio

Eli Lilly’s Kisunla Shows Reduced Brain Swelling with Modified Dosing Regimen in Alzheimer’s Patients

6 months ago talkbio0Tagged Alzheimer 's disease, ARIA-E, Cerebral Edema, Changing, dosing, Eli, Eli Lilly, Kisunla, Risk, Treatment Protocols

Eli Lilly, Kisunla, Alzheimer’s disease, brain swelling, modified dosing regimen, ARIA-E risk reduction

Vertex’s Non-Opioid Pain Drug Suzetrigine Nears FDA Approval: A Breakthrough in Acute Pain Management

7 months ago talkbio0Tagged acute pain management, addiction, Approved, Feeling relief, non-opioid pain drug, Opioid Epidemic, Pain, Risk, signal inhibitor, Suzetrigine, United States Food and Drug Administration

Suzetrigine, Non-opioid pain drug, Acute pain management, FDA approval, Vertex Pharmaceuticals, NaV1.8 pain signal inhibitor, Opioid epidemic, Pain relief without addiction risk

AI Guidance for Investors: Navigating the Future with Strategic Approaches and Regulatory Insights

8 months ago talkbio0Tagged Adoption, Advice, Artificial Intelligence, Computer Security, governance, Health care facility, investors, Mapping Strategies, Regulatory Impact, Risk, Strategic AI

AI Guidance for Investors, Strategic AI Adoption, Regulatory Impact on AI, Cybersecurity Risks in AI, AI Mapping Strategies, Data Governance in AI, Future of AI in Healthcare

BIOSECURE Act Clears House Hurdle, Heads to Senate for Vote on Restricting Chinese Biotech Ties

8 months ago talkbio0Tagged BIOSECURE, Biotech Companies, Biotechnology, Chinese Language, Drug Industry, drug supply chain, innovation, National Security, Risk, Senate, United States, US House of Representatives, Voting

BIOSECURE Act, House of Representatives, Senate Vote, Chinese Biotech Companies, National Security Risks, U.S. Pharmaceutical Industry, Biotechnology Innovation, Drug Supply Chain

Launching a Product in Europe: Understanding Supply Chain Cost Drivers

8 months ago talkbio0Tagged Administration occupational activities, European (ethnic group), Financial cost, Market, Reusable Drivers, Risk, Supply Chain Cost Analysis, supply chain management

Supply Chain Cost Analysis, European Market, Cost Drivers, Supply Chain Management, Risk Management

WuXi Biologics’ ADC Spinout Sees Revenue Surge Amid Biosecure Threat

9 months ago talkbio0Tagged bioconjugate, Biological Factors, BIOSECURE, CRDMO, Market, Risk, therapeutic autologous dendritic cells, WuXi

WuXi Biologics, ADC spinout, revenue jump, Biosecure risk, CRDMO, bioconjugate market

Novo Nordisk’s Wegovy Receives UK Approval to Reduce Cardiovascular Risks in Overweight and Obese Adults

10 months ago talkbio0Tagged Approved, Cardiovascular system, Glucagon-Like Peptide-1 Receptor, Nordisk, Obesity, Risk, semaglutide, UK, Wegovy

Wegovy, Novo Nordisk, UK approval, cardiovascular risks, weight loss, obesity, GLP-1 receptor agonist, semaglutide

Elion nets $81M to fund development of antifungal with lower toxicity risks

11 months ago talkbio0Tagged Antifungal Agents, Elion, Lower - spatial qualifier, Risk, Toxicity aspects

Antifungal Agents, Lower – spatial qualifier, Toxicity aspects, Risk, Elion

GSK’s RSV Vaccine Wins Expected Expansion into At-Risk Adults Aged 50-59

11 months ago talkbio0Tagged Adult, Age, Approved, Arexvy, Asthma, Chronic Obstructive Airway Disease, Diabetes, Heart failure, Increased, medical conditions, Respiratory syncytial virus, Respiratory Tract Diseases, Risk, SmithKline Beecham, United States Food and Drug Administration, Vaccines

GSK, RSV vaccine, Arexvy, FDA approval, adults aged 50-59, increased risk, respiratory syncytial virus, lower respiratory tract disease, medical conditions, chronic obstructive pulmonary disease, asthma, heart failure, diabetes.